ClinicalTrials.gg
CompletedNCT02311673Updated Jul 27, 2023Results posted

Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome

A Phase 2 interventional study of Setmelanotide and Placebo in Prader-Willi Syndrome, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 5 sites in United States. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-27.

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
16 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in Prader-Willi Syndrome with a site in United States — 9 open to participants now, 14 under way, 3 of them phase 3. Prader-Willi Syndrome · United States.

Enrollment
19th of 58
40 · median 23
Started
2015
with 3 others
Phase 2
17 of 69
1 open now
Registered
20th of 69
by date
Lead sponsor
3 of 69
Rhythm Pharmaceuticals, Inc.

Among the 69 studies in Prader-Willi Syndrome with a site in United States, this one is the 19th largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2015, is one of 17 in phase 2, and was the 20th registered.

Prader-Willi Syndrome

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

Browse Prader-Willi Syndrome studies →

Open to participants now

9 of the 69 studies in Prader-Willi Syndrome with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 16 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Prader-Willi Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the effects of a once daily subcutaneous injectable formulation of setmelanotide in obese participants with Prader-Willi syndrome on tolerability, weight loss, and hyperphagia-related behavior. The study drug (setmelanotide and placebo) was administered in a blinded fashion.

03

Conditions studied

  • Prader-Willi Syndrome

Keywords

  • Prader-Willi Syndrome
  • obesity
  • hyperphagia
04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. PWS due to chromosome 15 micro-deletion, maternal uniparental disomy, or imprinting defect, confirmed by fluorescent in situ hybridization, chromosomal microarray, and/or methylation studies. Obese male or female participants weighing at least 50 kilograms (kg) with (BMI) ≥ 27 kilogram per square meter (kg/m²)
  2. Age 16-65 years
  3. If a participant has diagnosis of type 2 diabetes, following criteria must be met:

    1. (HbA1c) \< 7.5% not being managed with insulin. Participants taking glucagon-like peptide-1 (GLP-1) analogues (exenatide or liraglutide) must have been on stable dose for greater than 3 months.
    2. Fasting plasma glucose \< 140 milligrams per deciliter (mg/dL)
    3. No history of ketoacidosis or hyperosmolar coma
  4. Vital signs must be within the following ranges and stable.

    1. Systolic blood pressure, 90-150 millimeter of mercury (mm Hg)
    2. Diastolic blood pressure, 50-90 mm Hg
    3. Pulse rate, 40-100 beats per minute (bpm)
  5. Stable body weight at home for approximately 2 months (self or guardian-reported loss/gain within ± 5%).
  6. Blood pressure (≤ 150/90 mmHg); may include stable dose (≥ 30 days of use) of up to two anti-hypertensive medications that are intended to remain on a stable dose during the protocol
  7. Parent or guardian is able to communicate well with the investigator, to understand and comply with the requirements of the study, and be able to understand and sign the written . Due to the significant intellectual disability with PWS, assent is to be provided by the participant who cannot consent for himself or herself.
  8. Results of screening clinical laboratory tests (complete blood count with differential and and chemistry profile) must be within normal range or, if outside of the normal range, must be accepted by the investigator and sponsor as not .
  9. Females of non-, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or for at least 12 months (and confirmed with a screening follicle-stimulating hormone (FSH) level in the post-menopausal lab range), do not require during the study. All other females of child-bearing potential must agree to use contraception as outlined in the protocol.
  10. Males with female partners of childbearing potential must agree to a double barrier method if they become sexually active during the study and for 90 days following the study. Male participants must not donate sperm for 90 days following their participation in the study.
  11. Participants must be on a stable dose of any allowed chronic concomitant medications while participating in the study.

Exclusion criteria

Exclusion Criteria:

  1. Recent use (within 3 month) of weight loss agents including herbal medication.
  2. Diagnosis of schizophrenia, bipolar disorder, personality disorder or other , Third Edition (DSM-III) disorders which the investigator believes will interfere significantly with study compliance.
  3. A Patient Health Questionnaire-9 (PHQ-9) score of ≥ 15.
  4. Any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS).
  5. illness in the 8 weeks before screening.
  6. History of clinically significant bleeding disorders.
  7. Current, clinically significant liver, renal, pulmonary, cardiac, oncologic, or gastrointestinal disease.
  8. Diagnosis of type 1 diabetes mellitus or other active endocrine disorders (e.g., Cushing syndrome, or thyroid dysfunction except if on adequate thyroid or replacement supplement).
  9. Cardiovascular disease event including history of congestive heart failure, coronary artery disease, myocardial infarction, second degree or greater heart block or prolonged syndrome.
  10. Blood pressure > 150/90 mm Hg.
  11. Liver disease or liver injury as indicated by abnormal liver function tests, , alkaline phosphatase, or serum (> 1.5 x for any of these tests) or history of hepatic cirrhosis.
  12. History or presence of impaired renal function as indicated by clinically significantly abnormal creatinine, blood urea nitrogen, or urinary constituents (e.g., albuminuria) or moderate to severe renal dysfunction as defined by the equation (\< 50 mL/min).
  13. History or close family history (parents or siblings) of melanoma.
  14. Oculocutaneous albinism (occurs at approximately 1% in PWS).
  15. Significant dermatologic findings as part of the Screening comprehensive skin evaluation performed by the dermatologist.
  16. Significant history of abuse of drugs or solvents in the year before screening or a positive Drugs of Abuse (DOA) test at screening.
  17. History of alcohol abuse in the past year before screening or currently drinks in excess of 21 units per week (3 servings or units/day).
  18. Caffeine consumption exceeding 6 cups of caffeinated tea/coffee (or equivalent) per day.
  19. Participant is, in the opinion of the Investigator, not suitable to participate in the study.
  20. Participation in any clinical study with an drug/device within 3 months prior to the first day of dosing.
  21. Positive history for (HIV), or tests or tuberculosis.
  22. Serious adverse reaction or significant to any drug.
  23. Clinically significant blood loss or blood donation > 500 milliliters (mL) within 3 months.
  24. Inadequate venous access.
  25. History of low blood counts or recurring infections.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Setmelanotide 0.5 mg

    Participants received setmelanotide 0.5 milligrams (mg) once daily as a subcutaneous injection from Day 15 to Day 41 (4-week, double-blind randomized treatment period) and Day 42 to Day 55 (2-week, randomized withdrawal period).

    Drug: Setmelanotide

  • Experimental
    Setmelanotide 1.5 mg

    Participants received setmelanotide 1.5 once daily as a subcutaneous injection from Day 15 to Day 41 (4-week, double-blind randomized treatment period), Day 42 to Day 55 (2-week, randomized withdrawal period), and Day 56 to Day 69 (optional 2-week, open-label extension period).

    Drug: Setmelanotide

  • Experimental
    Setmelanotide 2.5 mg

    Participants received setmelanotide 2.5 once daily as a subcutaneous injection from Day 15 to Day 41 (4-week, double-blind randomized treatment period), Day 42 to Day 55 (2-week, randomized withdrawal period), and Day 56 to Day 69 (optional 2-week, open-label extension period).

    Drug: Setmelanotide

  • Placebo comparator
    Placebo

    Participants received placebo matched to setmelanotide once daily as a subcutaneous injection from Day 1 to Day 14 (2-week, single-blind run-in period), Day 15 to Day 41 (4-week, double-blind randomized treatment period), and Day 42 to Day 55 (2-week, randomized withdrawal period).

    Drug: Placebo

Interventions

  • subcutaneous injection

    Also known as: RM-493

  • DrugPlacebo

    Subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE) - Period 2

    An adverse event (AE) was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE is considered to be treatment-emergent if the onset date/time is during or after administration of double-blind study drug or, in the event that onset time precedes double-blind study drug administration, the AE increases in severity during or after administration of double-blind study drug; in either case through 1-week after the last treatment dose. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent disability/incapacity; * Was a congenital anomaly/birth defect

    Time frame: Days 15 to 41

  2. Number of Participants Who Experienced a TEAE - Period 3

    An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE is considered to be treatment-emergent if the onset date/time is during or after administration of double-blind study drug or, in the event that onset time precedes double-blind study drug administration, the AE increases in severity during or after administration of double-blind study drug; in either case through 1-week after the last treatment dose. An SAE was any untoward medical occurrence that, at any dose: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent disability/incapacity; * Was a congenital anomaly/birth defect

    Time frame: Days 42 to 55

  3. Number of Participants Who Experienced a TEAE - Period 4

    An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE is considered to be treatment-emergent if the onset date/time is during or after administration of double-blind study drug or, in the event that onset time precedes double-blind study drug administration, the AE increases in severity during or after administration of double-blind study drug; in either case through 1-week after the last treatment dose. An SAE was any untoward medical occurrence that, at any dose: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent disability/incapacity; * Was a congenital anomaly/birth defect

    Time frame: Days 56 to 69

  4. Mean Body Weight - Period 2

    Time frame: Baseline (Day 15)

  5. Percent Change From Baseline in Body Weight - Period 2

    Time frame: Baseline (Day 15) and Day 42

  6. Overall Score of Prader-Willi Syndrome (PWS) Hyperphagia Questionnaire - Period 2

    The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Three factors identified from this questionnaire are: Hyperphagic Drive, Hyperphagic Behaviors, and Hyperphagic Severity. Items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Raw scores for each factor were used in data analyses, and the 3 domains were summed for an overall summary index of hyperphagia. Possible scores on the questionnaire range from a minimum score of 10 (no hyperphagia) to a maximum score of 50 (greater hyperphagia).

    Time frame: Baseline (Day 15)

  7. Percent Change From Baseline in Overall Score of Prader-Willi Syndrome (PWS) Hyperphagia Questionnaire - Period 2

    The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Three factors identified from this questionnaire are: Hyperphagic Drive, Hyperphagic Behaviors, and Hyperphagic Severity. Items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Raw scores for each factor were used in data analyses, and the 3 domains were summed for an overall summary index of hyperphagia. Possible scores on the questionnaire range from a minimum score of 10 (no hyperphagia) to a maximum score of 50 (greater hyperphagia). Percent change from baseline in overall score of PWS hyperphagia questionnaire is presented.

    Time frame: Baseline (Day 15) and Day 42

Secondary outcomes

  1. Percent Change From Baseline in Hyperphagic Drive Score of PWS Hyperphagia Questionnaire - Period 2

    The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Hyperphagic drive score assesses the persistence in asking for food based on 4 items. All 4 items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Possible scores for hyperphagic drive range from a minimum score of 4 (no hyperphagic drive) to a maximum score of 20 (greater hyperphagic drive). Percent change from baseline in hyperphagic drive score of PWS hyperphagia questionnaire is presented.

    Time frame: Baseline (Day 15) and Day 42

  2. Percent Change From Baseline in Hyperphagic Behaviors Score of PWS Hyperphagia Questionnaire - Period 2

    The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Hyperphagic behavior factor score assesses food seeking behaviors based on 4 items. All 4 items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Possible scores for hyperphagic behaviors range from a minimum score of 4 (no hyperphagic behavior) to a maximum score of 20 (greater hyperphagic behavior). Percent change from baseline in hyperphagic behaviors score of PWS hyperphagia questionnaire is presented.

    Time frame: Baseline (Day 15) and Day 42

  3. Percent Change From Baseline in Hyperphagic Severity Score of PWS Hyperphagia Questionnaire - Period 2

    The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Hyperphagic severity factor score assesses the severity of hyperphagia based on 2 items. Both items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Possible scores for hyperphagic severity range from a minimum score of 2 (no hyperphagic severity) to a maximum score of 10 (greater hyperphagic severity). Percent change from baseline in hyperphagic severity score of PWS hyperphagia questionnaire is presented.

    Time frame: Baseline (Day 15) and Day 42

  4. Percent Change From Baseline in Overall Score of PWS Hyperphagia Questionnaire - Period 3

    The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Three factors identified from this questionnaire are: Hyperphagic Drive, Hyperphagic Behaviors, and Hyperphagic Severity. Items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Raw scores for each factor were used in data analyses, and the 3 domains were summed for an overall summary index of hyperphagia. Possible scores on the questionnaire range from a minimum score of 10 (no hyperphagia) to a maximum score of 50 (greater hyperphagia). Percent change from baseline in overall score of PWS hyperphagia questionnaire is presented.

    Time frame: Baseline (Day 42) and Day 56

  5. Percent Change From Baseline in Overall Score of PWS Hyperphagia Questionnaire - Period 4

    The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Three factors identified from this questionnaire are: Hyperphagic Drive, Hyperphagic Behaviors, and Hyperphagic Severity. Items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Raw scores for each factor were used in data analyses, and the 3 domains were summed for an overall summary index of hyperphagia. Possible scores on the questionnaire range from a minimum score of 10 (no hyperphagia) to a maximum score of 50 (greater hyperphagia). Percent change from baseline in overall score of PWS hyperphagia questionnaire is presented.

    Time frame: Baseline (Day 56) and Day 70

  6. Mean Setmelanotide Trough Concentrations

    The average of setmelanotide trough concentrations values for both timepoints (5 minutes predose on Day 42 and Day 70) is presented.

    Time frame: 5 minutes predose on Day 42 and Day 70

  7. Maximum Drug Concentration (Cmax) of Setmelanotide During a 24-Hour Steady-State Interval

    Maximum drug concentration determined directly from individual concentration-time data.

    Time frame: Starting on any day from Day 63 through 69, a 24-hour PK profile obtained; blood samples were collected at 0 (within 5 minutes predose), 1, 2, 4, 6, 7, 8, 9, 10, 12, and 24 hours after dosing

  8. Time to the Maximum Drug Concentration (Tmax) of Setmelanotide During a 24-Hour Steady-State Interval

    Maximum drug concentration determined directly from individual concentration-time data.

    Time frame: Starting on any day from Day 63 through 69, a 24-hour PK profile obtained; blood samples were collected at 0 (within 5 minutes predose), 1, 2, 4, 6, 7, 8, 9, 10, 12, and 24 hours after dosing

  9. Area Under the Drug Concentration-Time Curve From Time-Zero to 24 Hours Postdose (AUC24h) of Setmelanotide During a 24-Hour Steady-State Interval

    Time frame: Starting on any day from Day 63 through 69, a 24-hour PK profile obtained; blood samples were collected at 0 (within 5 minutes predose), 1, 2, 4, 6, 7, 8, 9, 10, 12, and 24 hours after dosing

  10. Volume of Distribution (Vd) of Setmelanotide During a 24-Hour Steady-State Interval

    Volume of distribution calculated as Dose/The observed terminal rate constant\*AUC24h.

    Time frame: Starting on any day from Day 63 through 69, a 24-hour PK profile obtained; blood samples were collected at 0 (within 5 minutes predose), 1, 2, 4, 6, 7, 8, 9, 10, 12, and 24 hours after dosing

  11. Total Clearance (CL) of Setmelanotide During a 24-Hour Steady-State Interval

    Clearance after extravascular administration; calculated as Dose/AUC24h.

    Time frame: Starting on any day from Day 63 through 69, a 24-hour PK profile obtained; blood samples were collected at 0 (within 5 minutes predose), 1, 2, 4, 6, 7, 8, 9, 10, 12, and 24 hours after dosing

  12. Change From Baseline in Body Weight - Period 2

    Time frame: Baseline (Day 15) and Day 42

  13. Percent Change From Baseline in Body Weight - Period 3

    Time frame: Baseline (Day 42) and Day 56

  14. Percent Change From Baseline in Body Weight - Period 4

    Time frame: Baseline (Day 56) and Day 70

  15. Percent Change From Baseline in Body Weight for Continuous Active and Continuous Placebo Treatments - Period 2 and 3

    Time frame: Baseline (Day 15), Day 42, Day 56

  16. Percent Change From Baseline in Body Fat Measured Using Dual x-Ray Absorptiometry (DEXA) - Period 2

    Total body fat was assessed by DEXA scan.

    Time frame: Baseline (Day 15) and Day 42

  17. Number of Participants With Clinically Significant Percent Change From Baseline in Body Fat Measured Using DEXA - Period 4

    Total body fat was assessed by DEXA scan. Number of participants with clinically significant percent change from baseline in body fat were judged by investigator.

    Time frame: Baseline (Day 56) and Day 70

  18. Percent Change From Baseline in Body Mass Measured Using DEXA - Period 2

    Total body mass was assessed by DEXA scan.

    Time frame: Baseline (Day 15) and Day 42

  19. Number of Participants With Clinically Significant Percent Change From Baseline in Body Mass Measured Using DEXA - Period 4

    Total body mass was assessed by DEXA scan. Number of participants with clinically significant percent change from baseline in body mass were judged by investigator.

    Time frame: Baseline (Day 56) and Day 70

07

Results

Posted Jul 27, 2023

Participant flow

Placebo Run-in Period 1 (2 Weeks)
Participant flow — Placebo Run-in Period 1 (2 Weeks)
MilestoneSetmelanotide 0.5 mgSetmelanotide 1.5 mgSetmelanotide 2.5 mgPlacebo
Started00040
Completed00040
Not completed0000
Double-blind Randomized Period 2 (4 Wks)
Participant flow — Double-blind Randomized Period 2 (4 Wks)
MilestoneSetmelanotide 0.5 mgSetmelanotide 1.5 mgSetmelanotide 2.5 mgPlacebo
Started413815
Completed413715
Not completed0010
Withdrew: Withdrawal by participant and investigator decision0010
Randomized Withdrawal Period 3 (2 Weeks)
Participant flow — Randomized Withdrawal Period 3 (2 Weeks)
MilestoneSetmelanotide 0.5 mgSetmelanotide 1.5 mgSetmelanotide 2.5 mgPlacebo
Started310520
Completed310520
Not completed0000
Open-label Extension Period 4 (2 Weeks)
Participant flow — Open-label Extension Period 4 (2 Weeks)
MilestoneSetmelanotide 0.5 mgSetmelanotide 1.5 mgSetmelanotide 2.5 mgPlacebo
Started022161
Completed022161
Not completed0000

Outcome measures

PrimaryNumber of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE) - Period 2

An adverse event (AE) was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE is considered to be treatment-emergent if the onset date/time is during or after administration of double-blind study drug or, in the event that onset time precedes double-blind study drug administration, the AE increases in severity during or after administration of double-blind study drug; in either case through 1-week after the last treatment dose. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent disability/incapacity; * Was a congenital anomaly/birth defect

Time frame:
Days 15 to 41
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE) - Period 2
ParticipantsSetmelanotide 0.5 mg (Double-blind Randomized Treatment)Setmelanotide 1.5 mg (Double-blind Randomized Treatment)Setmelanotide 2.5 mg (Double-blind Randomized Treatment)Placebo (Double-blind Randomized Treatment)
Participants with at least 1 TEAE411611
Participants with at least 1 SAE0000
PrimaryNumber of Participants Who Experienced a TEAE - Period 3

An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE is considered to be treatment-emergent if the onset date/time is during or after administration of double-blind study drug or, in the event that onset time precedes double-blind study drug administration, the AE increases in severity during or after administration of double-blind study drug; in either case through 1-week after the last treatment dose. An SAE was any untoward medical occurrence that, at any dose: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent disability/incapacity; * Was a congenital anomaly/birth defect

Time frame:
Days 42 to 55
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a TEAE - Period 3
ParticipantsSetmelanotide 0.5 mg (Randomized Withdrawal Period)Setmelanotide 1.5 mg (Randomized Withdrawal Period)Setmelanotide 2.5 mg (Randomized Withdrawal Period)Placebo (Randomized Withdrawal Period)
Participants with at least 1 TEAE37411
Participants with at least 1 SAE0000
PrimaryNumber of Participants Who Experienced a TEAE - Period 4

An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE is considered to be treatment-emergent if the onset date/time is during or after administration of double-blind study drug or, in the event that onset time precedes double-blind study drug administration, the AE increases in severity during or after administration of double-blind study drug; in either case through 1-week after the last treatment dose. An SAE was any untoward medical occurrence that, at any dose: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent disability/incapacity; * Was a congenital anomaly/birth defect

Time frame:
Days 56 to 69
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a TEAE - Period 4
ParticipantsSetmelanotide 1.5 mg (Open-Label Extension)Setmelanotide 2.5 mg (Open-Label Extension)Placebo (Open-Label Extension)
Participants with at least 1 TEAE17120
Participants with at least 1 SAE000
PrimaryMean Body Weight - Period 2
Time frame:
Baseline (Day 15)
Reported as:
Mean · Kilograms (kg)
Mean Body Weight - Period 2
Kilograms (kg)Setmelanotide 0.5 mg (Double-blind Randomized Treatment)Setmelanotide 1.5 mg (Double-blind Randomized Treatment)Setmelanotide 2.5 mg (Double-blind Randomized Treatment)Placebo (Double-blind Randomized Treatment)
Mean Body Weight - Period 294.3 ± 16.8492.7 ± 5.50101.6 ± 5.35102.2 ± 9.16
PrimaryPercent Change From Baseline in Body Weight - Period 2
Time frame:
Baseline (Day 15) and Day 42
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Body Weight - Period 2
percent changeSetmelanotide 0.5 mg (Double-blind Randomized Treatment)Setmelanotide 1.5 mg (Double-blind Randomized Treatment)Setmelanotide 2.5 mg (Double-blind Randomized Treatment)Placebo (Double-blind Randomized Treatment)
Percent Change From Baseline in Body Weight - Period 2-0.7 (-3.1 to 1.8)-0.8 (-2.2 to 0.6)0.4 (-1.2 to 2.0)-0.4 (-1.8 to 0.9)
Statistical analysis
  • Setmelanotide 0.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.420 (One sided p-value.) · Least squares (ls) mean difference: -0.3 · 95% CI -3.1 to 2.5A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
  • Setmelanotide 1.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.348 · Ls mean difference: -0.4 · 95% CI -2.3 to 1.6A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
  • Setmelanotide 2.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.779 (One sided p-value.) · Ls mean difference: 0.8 · 95% CI -1.3 to 2.9A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
PrimaryOverall Score of Prader-Willi Syndrome (PWS) Hyperphagia Questionnaire - Period 2

The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Three factors identified from this questionnaire are: Hyperphagic Drive, Hyperphagic Behaviors, and Hyperphagic Severity. Items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Raw scores for each factor were used in data analyses, and the 3 domains were summed for an overall summary index of hyperphagia. Possible scores on the questionnaire range from a minimum score of 10 (no hyperphagia) to a maximum score of 50 (greater hyperphagia).

Time frame:
Baseline (Day 15)
Reported as:
Mean · units on a scale
Overall Score of Prader-Willi Syndrome (PWS) Hyperphagia Questionnaire - Period 2
units on a scaleSetmelanotide 0.5 mg (Double-blind Randomized Treatment)Setmelanotide 1.5 mg (Double-blind Randomized Treatment)Setmelanotide 2.5 mg (Double-blind Randomized Treatment)Placebo (Double-blind Randomized Treatment)
Overall Score of Prader-Willi Syndrome (PWS) Hyperphagia Questionnaire - Period 231.0 ± 2.8621.2 ± 2.2820.2 ± 2.7918.7 ± 2.33
PrimaryPercent Change From Baseline in Overall Score of Prader-Willi Syndrome (PWS) Hyperphagia Questionnaire - Period 2

The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Three factors identified from this questionnaire are: Hyperphagic Drive, Hyperphagic Behaviors, and Hyperphagic Severity. Items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Raw scores for each factor were used in data analyses, and the 3 domains were summed for an overall summary index of hyperphagia. Possible scores on the questionnaire range from a minimum score of 10 (no hyperphagia) to a maximum score of 50 (greater hyperphagia). Percent change from baseline in overall score of PWS hyperphagia questionnaire is presented.

Time frame:
Baseline (Day 15) and Day 42
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Overall Score of Prader-Willi Syndrome (PWS) Hyperphagia Questionnaire - Period 2
percent changeSetmelanotide 0.5 mg (Double-blind Randomized Treatment)Setmelanotide 1.5 mg (Double-blind Randomized Treatment)Setmelanotide 2.5 mg (Double-blind Randomized Treatment)Placebo (Double-blind Randomized Treatment)
Percent Change From Baseline in Overall Score of Prader-Willi Syndrome (PWS) Hyperphagia Questionnaire - Period 220.2 (-8.7 to 49.1)-5.2 (-21.3 to 10.9)-5.0 (-23.7 to 13.6)-1.3 (-16.9 to 14.3)
Statistical analysis
  • Setmelanotide 0.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.901 (One sided p-value.) · Ls mean difference: 21.5 · 95% CI -11.8 to 54.8A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
  • Setmelanotide 1.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.362 (One sided p-value.) · Ls mean difference: -3.9 · 95% CI -26.3 to 18.5A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
  • Setmelanotide 2.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.378 (One sided p-value.) · Ls mean difference: -3.7 · 95% CI -28.0 to 20.5A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
SecondaryPercent Change From Baseline in Hyperphagic Drive Score of PWS Hyperphagia Questionnaire - Period 2

The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Hyperphagic drive score assesses the persistence in asking for food based on 4 items. All 4 items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Possible scores for hyperphagic drive range from a minimum score of 4 (no hyperphagic drive) to a maximum score of 20 (greater hyperphagic drive). Percent change from baseline in hyperphagic drive score of PWS hyperphagia questionnaire is presented.

Time frame:
Baseline (Day 15) and Day 42
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Hyperphagic Drive Score of PWS Hyperphagia Questionnaire - Period 2
percent changeSetmelanotide 0.5 mg (Double-blind Randomized Treatment)Setmelanotide 1.5 mg (Double-blind Randomized Treatment)Setmelanotide 2.5 mg (Double-blind Randomized Treatment)Placebo (Double-blind Randomized Treatment)
Percent Change From Baseline in Hyperphagic Drive Score of PWS Hyperphagia Questionnaire - Period 227.2 (-8.9 to 63.3)-3.6 (-24.1 to 16.9)-6.8 (-30.5 to 16.8)6.6 (-13.2 to 26.4)
Statistical analysis
  • Setmelanotide 0.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.840 (One sided p-value.) · Ls mean difference: 20.6 · 95% CI -20.9 to 62.2A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
  • Setmelanotide 1.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.236 (One sided p-value.) · Ls mean difference: -10.2 · 95% CI -38.7 to 18.4A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
  • Setmelanotide 2.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.191 · Ls mean difference: -13.4 · 95% CI -44.2 to 17.4One sided p-value.
SecondaryPercent Change From Baseline in Hyperphagic Behaviors Score of PWS Hyperphagia Questionnaire - Period 2

The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Hyperphagic behavior factor score assesses food seeking behaviors based on 4 items. All 4 items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Possible scores for hyperphagic behaviors range from a minimum score of 4 (no hyperphagic behavior) to a maximum score of 20 (greater hyperphagic behavior). Percent change from baseline in hyperphagic behaviors score of PWS hyperphagia questionnaire is presented.

Time frame:
Baseline (Day 15) and Day 42
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Hyperphagic Behaviors Score of PWS Hyperphagia Questionnaire - Period 2
percent changeSetmelanotide 0.5 mg (Double-blind Randomized Treatment)Setmelanotide 1.5 mg (Double-blind Randomized Treatment)Setmelanotide 2.5 mg (Double-blind Randomized Treatment)Placebo (Double-blind Randomized Treatment)
Percent Change From Baseline in Hyperphagic Behaviors Score of PWS Hyperphagia Questionnaire - Period 219.1 (-19.3 to 57.5)-1.7 (-22.3 to 18.9)-3.0 (-26.8 to 20.8)-0.4 (-20.4 to 19.6)
Statistical analysis
  • Setmelanotide 0.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.812 (One sided p-value.) · Ls mean difference: 19.5 · 95% CI -24.8 to 63.8
  • Setmelanotide 1.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.464 (One sided p-value.) · Ls mean difference: -1.3 · 95% CI -29.9 to 27.4A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
  • Setmelanotide 2.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.432 (One sided p-value.) · Ls mean difference: -2.6 · 95% CI -33.6 to 28.4A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
SecondaryPercent Change From Baseline in Hyperphagic Severity Score of PWS Hyperphagia Questionnaire - Period 2

The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Hyperphagic severity factor score assesses the severity of hyperphagia based on 2 items. Both items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Possible scores for hyperphagic severity range from a minimum score of 2 (no hyperphagic severity) to a maximum score of 10 (greater hyperphagic severity). Percent change from baseline in hyperphagic severity score of PWS hyperphagia questionnaire is presented.

Time frame:
Baseline (Day 15) and Day 42
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Hyperphagic Severity Score of PWS Hyperphagia Questionnaire - Period 2
percent changeSetmelanotide 0.5 mg (Double-blind Randomized Treatment)Setmelanotide 1.5 mg (Double-blind Randomized Treatment)Setmelanotide 2.5 mg (Double-blind Randomized Treatment)Placebo (Double-blind Randomized Treatment)
Percent Change From Baseline in Hyperphagic Severity Score of PWS Hyperphagia Questionnaire - Period 233.2 (-4.4 to 70.9)-0.7 (-22.1 to 20.6)5.5 (-19.1 to 30.2)-16.7 (-37.3 to 3.9)
Statistical analysis
  • Setmelanotide 0.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.988 (One sided p-value.) · Ls mean difference: 49.9 · 95% CI 6.7 to 93.2A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
  • Setmelanotide 1.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.859 (One sided p-value.) · Ls mean difference: 16.0 · 95% CI -13.7 to 45.6A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
  • Setmelanotide 2.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.916 (One sided p-value.) · Ls mean difference: 22.2 · 95% CI -9.8 to 54.3A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
SecondaryPercent Change From Baseline in Overall Score of PWS Hyperphagia Questionnaire - Period 3

The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Three factors identified from this questionnaire are: Hyperphagic Drive, Hyperphagic Behaviors, and Hyperphagic Severity. Items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Raw scores for each factor were used in data analyses, and the 3 domains were summed for an overall summary index of hyperphagia. Possible scores on the questionnaire range from a minimum score of 10 (no hyperphagia) to a maximum score of 50 (greater hyperphagia). Percent change from baseline in overall score of PWS hyperphagia questionnaire is presented.

Time frame:
Baseline (Day 42) and Day 56
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Overall Score of PWS Hyperphagia Questionnaire - Period 3
percent changeSetmelanotide 0.5 mg (Randomized Withdrawal Period)Setmelanotide 1.5 mg (Randomized Withdrawal Period)Setmelanotide 2.5 mg (Randomized Withdrawal Period)Placebo (Randomized Withdrawal Period)
Percent Change From Baseline in Overall Score of PWS Hyperphagia Questionnaire - Period 335.0 (-2.9 to 72.9)-1.8 (-18.4 to 14.7)3.4 (-20.1 to 26.9)2.3 (-9.6 to 14.2)
Statistical analysis
  • Setmelanotide 0.5 mg (Randomized Withdrawal Period) vs Placebo (Randomized Withdrawal Period) · Longitudinal mixed analysis of variance · p = 0.943 (One sided p-value.) · Ls mean difference: 32.7 · 95% CI -8.4 to 73.8A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
  • Setmelanotide 1.5 mg (Randomized Withdrawal Period) vs Placebo (Randomized Withdrawal Period) · Longitudinal mixed analysis of variance · p = 0.339 (One sided p-value.) · Ls mean difference: -4.2 · 95% CI -24.4 to 16.1A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
  • Setmelanotide 2.5 mg (Randomized Withdrawal Period) vs Placebo (Randomized Withdrawal Period) · Longitudinal mixed analysis of variance · p = 0.533 (One sided p-value.) · Ls mean difference: 1.1 · 95% CI -25.0 to 27.2A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
SecondaryPercent Change From Baseline in Overall Score of PWS Hyperphagia Questionnaire - Period 4

The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Three factors identified from this questionnaire are: Hyperphagic Drive, Hyperphagic Behaviors, and Hyperphagic Severity. Items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Raw scores for each factor were used in data analyses, and the 3 domains were summed for an overall summary index of hyperphagia. Possible scores on the questionnaire range from a minimum score of 10 (no hyperphagia) to a maximum score of 50 (greater hyperphagia). Percent change from baseline in overall score of PWS hyperphagia questionnaire is presented.

Time frame:
Baseline (Day 56) and Day 70
Reported as:
Mean · percent change
Percent Change From Baseline in Overall Score of PWS Hyperphagia Questionnaire - Period 4
percent changeSetmelanotide 1.5 mg (Open-Label Extension)Setmelanotide 2.5 mg (Open-Label Extension)
Percent Change From Baseline in Overall Score of PWS Hyperphagia Questionnaire - Period 4-0.9 ± 23.21-0.4 ± 29.94
SecondaryMean Setmelanotide Trough Concentrations

The average of setmelanotide trough concentrations values for both timepoints (5 minutes predose on Day 42 and Day 70) is presented.

Time frame:
5 minutes predose on Day 42 and Day 70
Reported as:
Mean · nanograms per milliliter (ng/mL)
Mean Setmelanotide Trough Concentrations
nanograms per milliliter (ng/mL)Setmelanotide 0.5 mgSetmelanotide 1.5 mgSetmelanotide 2.5 mg
Mean Setmelanotide Trough Concentrations0.790 ± 0.3362.59 ± 1.515.63 ± 4.19
SecondaryMaximum Drug Concentration (Cmax) of Setmelanotide During a 24-Hour Steady-State Interval

Maximum drug concentration determined directly from individual concentration-time data.

Time frame:
Starting on any day from Day 63 through 69, a 24-hour PK profile obtained; blood samples were collected at 0 (within 5 minutes predose), 1, 2, 4, 6, 7, 8, 9, 10, 12, and 24 hours after dosing
Reported as:
Mean · ng/mL
Maximum Drug Concentration (Cmax) of Setmelanotide During a 24-Hour Steady-State Interval
ng/mLSetmelanotide 2.5 mg (Open-Label Extension)
Maximum Drug Concentration (Cmax) of Setmelanotide During a 24-Hour Steady-State Interval39.1 ± 12.2
SecondaryTime to the Maximum Drug Concentration (Tmax) of Setmelanotide During a 24-Hour Steady-State Interval

Maximum drug concentration determined directly from individual concentration-time data.

Time frame:
Starting on any day from Day 63 through 69, a 24-hour PK profile obtained; blood samples were collected at 0 (within 5 minutes predose), 1, 2, 4, 6, 7, 8, 9, 10, 12, and 24 hours after dosing
Reported as:
Median · hours (hr)
Time to the Maximum Drug Concentration (Tmax) of Setmelanotide During a 24-Hour Steady-State Interval
hours (hr)Setmelanotide 2.5 mg (Open-Label Extension)
Time to the Maximum Drug Concentration (Tmax) of Setmelanotide During a 24-Hour Steady-State Interval6.00 (5.95 to 10.15)
SecondaryArea Under the Drug Concentration-Time Curve From Time-Zero to 24 Hours Postdose (AUC24h) of Setmelanotide During a 24-Hour Steady-State Interval
Time frame:
Starting on any day from Day 63 through 69, a 24-hour PK profile obtained; blood samples were collected at 0 (within 5 minutes predose), 1, 2, 4, 6, 7, 8, 9, 10, 12, and 24 hours after dosing
Reported as:
Mean · hr*ng/mL
Area Under the Drug Concentration-Time Curve From Time-Zero to 24 Hours Postdose (AUC24h) of Setmelanotide During a 24-Hour Steady-State Interval
hr*ng/mLSetmelanotide 2.5 mg (Open-Label Extension)
Area Under the Drug Concentration-Time Curve From Time-Zero to 24 Hours Postdose (AUC24h) of Setmelanotide During a 24-Hour Steady-State Interval569.4 ± 190.6
SecondaryVolume of Distribution (Vd) of Setmelanotide During a 24-Hour Steady-State Interval

Volume of distribution calculated as Dose/The observed terminal rate constant\*AUC24h.

Time frame:
Starting on any day from Day 63 through 69, a 24-hour PK profile obtained; blood samples were collected at 0 (within 5 minutes predose), 1, 2, 4, 6, 7, 8, 9, 10, 12, and 24 hours after dosing
Reported as:
Mean · Liters (L)
Volume of Distribution (Vd) of Setmelanotide During a 24-Hour Steady-State Interval
Liters (L)Setmelanotide 2.5 mg (Open-Label Extension)
Volume of Distribution (Vd) of Setmelanotide During a 24-Hour Steady-State Interval52.8 ± 10.0
SecondaryTotal Clearance (CL) of Setmelanotide During a 24-Hour Steady-State Interval

Clearance after extravascular administration; calculated as Dose/AUC24h.

Time frame:
Starting on any day from Day 63 through 69, a 24-hour PK profile obtained; blood samples were collected at 0 (within 5 minutes predose), 1, 2, 4, 6, 7, 8, 9, 10, 12, and 24 hours after dosing
Reported as:
Mean · L/hr
Total Clearance (CL) of Setmelanotide During a 24-Hour Steady-State Interval
L/hrSetmelanotide 2.5 mg (Open-Label Extension)
Total Clearance (CL) of Setmelanotide During a 24-Hour Steady-State Interval4.77 ± 1.49
SecondaryChange From Baseline in Body Weight - Period 2
Time frame:
Baseline (Day 15) and Day 42
Reported as:
Least squares mean · kg
Change From Baseline in Body Weight - Period 2
kgSetmelanotide 0.5 mg (Double-blind Randomized Treatment)Setmelanotide 1.5 mg (Double-blind Randomized Treatment)Setmelanotide 2.5 mg (Double-blind Randomized Treatment)Placebo (Double-blind Randomized Treatment)
Change From Baseline in Body Weight - Period 2-0.6 (-3.1 to 1.8)-0.8 (-2.2 to 0.7)0.3 (-1.4 to 1.9)-0.4 (-1.8 to 1.0)
Statistical analysis
  • Setmelanotide 0.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.439 (One sided p-value.) · Ls mean difference: -0.2 · 95% CI -3.0 to 2.6A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
  • Setmelanotide 1.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.366 (One sided p-value.) · Ls mean difference: -0.3 · 95% CI -2.3 to 1.6A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
  • Setmelanotide 2.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.744 (One sided p-value.) · Ls mean difference: 0.7 · 95% CI -1.4 to 2.8A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
SecondaryPercent Change From Baseline in Body Weight - Period 3
Time frame:
Baseline (Day 42) and Day 56
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Body Weight - Period 3
percent changeSetmelanotide 0.5 mg (Randomized Withdrawal Period)Setmelanotide 1.5 mg (Randomized Withdrawal Period)Setmelanotide 2.5 mg (Randomized Withdrawal Period)Placebo (Randomized Withdrawal Period)
Percent Change From Baseline in Body Weight - Period 31.3 (-0.3 to 2.9)0.0 (-0.9 to 0.9)0.0 (-1.3 to 1.3)0.2 (-0.4 to 0.9)
Statistical analysis
  • Setmelanotide 0.5 mg (Randomized Withdrawal Period) vs Placebo (Randomized Withdrawal Period) · Longitudinal mixed analysis of variance · p = 0.883 (One sided p-value.) · Ls mean difference: 1.0 · 95% CI -0.7 to 2.8A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
  • Setmelanotide 1.5 mg (Randomized Withdrawal Period) vs Placebo (Randomized Withdrawal Period) · Longitudinal mixed analysis of variance · p = 0.338 (One sided p-value.) · Ls mean difference: -0.2 · 95% CI -1.3 to 0.9A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
  • Setmelanotide 2.5 mg (Randomized Withdrawal Period) vs Placebo (Randomized Withdrawal Period) · Longitudinal mixed analysis of variance · p = 0.381 (One sided p-value.) · Ls mean difference: -0.2 · 95% CI -1.6 to 1.2A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
SecondaryPercent Change From Baseline in Body Weight - Period 4
Time frame:
Baseline (Day 56) and Day 70
Reported as:
Mean · percent change
Percent Change From Baseline in Body Weight - Period 4
percent changeSetmelanotide 1.5 mg (Open-Label Extension)Setmelanotide 2.5 mg (Open-Label Extension)
Percent Change From Baseline in Body Weight - Period 4-0.0 ± 0.900.0 ± 2.70
SecondaryPercent Change From Baseline in Body Weight for Continuous Active and Continuous Placebo Treatments - Period 2 and 3
Time frame:
Baseline (Day 15), Day 42, Day 56
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Body Weight for Continuous Active and Continuous Placebo Treatments - Period 2 and 3
percent changeSetmelanotide 0.5 mg (Double-blind Randomized Treatment, Then Randomized Withdrawal Period)Setmelanotide 1.5 mg (Double-blind Randomized Treatment, Then Randomized Withdrawal Period)Setmelanotide 2.5 mg (Double-blind Randomized Treatment, Then Randomized Withdrawal Period)Placebo (Double-blind Randomized Treatment), Then Placebo (Randomized Withdrawal Period)
Percent change at Day 42-0.7 (-5.3 to 3.9)-0.5 (-3.1 to 2.2)0.7 (-2.6 to 4.0)-0.7 (-3.2 to 1.7)
Percent change at Day 560.2 (-4.8 to 5.3)-0.4 (-3.3 to 2.6)0.9 (-2.7 to 4.4)-1.0 (-3.8 to 1.7)
Statistical analysis
  • Setmelanotide 0.5 mg (Double-blind Randomized Treatment, Then Randomized Withdrawal Period) vs Placebo (Double-blind Randomized Treatment), Then Placebo (Randomized Withdrawal Period) · Longitudinal mixed analysis of variance · p = 0.679 (One sided p-value.) · Ls mean difference: 1.3 · 95% CI -4.5 to 7.0A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
  • Setmelanotide 1.5 mg (Double-blind Randomized Treatment, Then Randomized Withdrawal Period) vs Placebo (Double-blind Randomized Treatment), Then Placebo (Randomized Withdrawal Period) · Longitudinal mixed analysis of variance · p = 0.641 (One sided p-value.) · Ls mean difference: 0.7 · 95% CI -3.3 to 4.7A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
  • Setmelanotide 2.5 mg (Double-blind Randomized Treatment, Then Randomized Withdrawal Period) vs Placebo (Double-blind Randomized Treatment), Then Placebo (Randomized Withdrawal Period) · Longitudinal mixed analysis of variance · p = 0.809 (One sided p-value.) · Ls mean difference: 1.9 · 95% CI -2.6 to 6.4A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
SecondaryPercent Change From Baseline in Body Fat Measured Using Dual x-Ray Absorptiometry (DEXA) - Period 2

Total body fat was assessed by DEXA scan.

Time frame:
Baseline (Day 15) and Day 42
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Body Fat Measured Using Dual x-Ray Absorptiometry (DEXA) - Period 2
percent changeSetmelanotide 0.5 mg (Double-blind Randomized Treatment)Setmelanotide 1.5 mg (Double-blind Randomized Treatment)Setmelanotide 2.5 mg (Double-blind Randomized Treatment)Placebo (Double-blind Randomized Treatment)
Percent Change From Baseline in Body Fat Measured Using Dual x-Ray Absorptiometry (DEXA) - Period 2-0.6 (-3.4 to 2.1)-1.1 (-2.7 to 0.5)-0.7 (-2.6 to 1.3)-1.1 (-2.7 to 0.4)
Statistical analysis
  • Setmelanotide 0.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.633 (One sided p-value.) · Ls mean difference: 0.5 · 95% CI -2.6 to 3.6A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
  • Setmelanotide 1.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.528 (One sided p-value.) · Ls mean difference: 0.1 · 95% CI -2.1 to 2.3A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
  • Setmelanotide 2.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.648 (One sided p-value.) · Ls mean difference: 0.5 · 95% CI -2.0 to 2.9A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
SecondaryNumber of Participants With Clinically Significant Percent Change From Baseline in Body Fat Measured Using DEXA - Period 4

Total body fat was assessed by DEXA scan. Number of participants with clinically significant percent change from baseline in body fat were judged by investigator.

Time frame:
Baseline (Day 56) and Day 70
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Percent Change From Baseline in Body Fat Measured Using DEXA - Period 4
ParticipantsSetmelanotide 1.5 mg (Open-Label Extension)Setmelanotide 2.5 mg (Open-Label Extension)
Number of Participants With Clinically Significant Percent Change From Baseline in Body Fat Measured Using DEXA - Period 400
SecondaryPercent Change From Baseline in Body Mass Measured Using DEXA - Period 2

Total body mass was assessed by DEXA scan.

Time frame:
Baseline (Day 15) and Day 42
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Body Mass Measured Using DEXA - Period 2
percent changeSetmelanotide 0.5 mg (Double-blind Randomized Treatment)Setmelanotide 1.5 mg (Double-blind Randomized Treatment)Setmelanotide 2.5 mg (Double-blind Randomized Treatment)Placebo (Double-blind Randomized Treatment)
Percent Change From Baseline in Body Mass Measured Using DEXA - Period 2-0.2 (-2.3 to 1.9)-1.1 (-2.3 to 0.2)-0.3 (-1.8 to 1.2)-0.9 (-2.1 to 0.3)
Statistical analysis
  • Setmelanotide 0.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.712 (One sided p-value.) · Ls mean difference: 0.7 · 95% CI -1.8 to 3.1A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
  • Setmelanotide 1.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.414 (One sided p-value.) · Ls mean difference: -0.2 · 95% CI -1.9 to 1.5A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
  • Setmelanotide 2.5 mg (Double-blind Randomized Treatment) vs Placebo (Double-blind Randomized Treatment) · Longitudinal mixed analysis of variance · p = 0.732 (One sided p-value) · Ls mean difference: 0.6 · 95% CI -1.3 to 2.5A longitudinal mixed analysis of variance model with fixed effects for treatment, time, treatment-by-time interaction, treatment-by-baseline weight interaction, baseline weight as covariate and participant as random effect was used.
SecondaryNumber of Participants With Clinically Significant Percent Change From Baseline in Body Mass Measured Using DEXA - Period 4

Total body mass was assessed by DEXA scan. Number of participants with clinically significant percent change from baseline in body mass were judged by investigator.

Time frame:
Baseline (Day 56) and Day 70
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Percent Change From Baseline in Body Mass Measured Using DEXA - Period 4
ParticipantsSetmelanotide 1.5 mg (Open-Label Extension)Setmelanotide 2.5 mg (Open-Label Extension)
Number of Participants With Clinically Significant Percent Change From Baseline in Body Mass Measured Using DEXA - Period 400

Adverse events

Collected over Day 15 to Day 69. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Setmelanotide 0.5 mg (Double-blind Randomized Treatment)0/4 (0%)0/4 (0%)4/4 (100%)
Setmelanotide 1.5 mg (Double-blind Randomized Treatment)0/13 (0%)0/13 (0%)11/13 (84.6%)
Setmelanotide 2.5 mg (Double-blind Randomized Treatment)0/8 (0%)0/8 (0%)6/8 (75%)
Placebo (Double-blind Randomized Treatment)0/15 (0%)0/15 (0%)11/15 (73.3%)
Setmelanotide 0.5 mg (Randomized Withdrawal Period)0/3 (0%)0/3 (0%)3/3 (100%)
Setmelanotide 1.5 mg (Randomized Withdrawal Period)0/10 (0%)0/10 (0%)7/10 (70%)
Setmelanotide 2.5 mg (Randomized Withdrawal Period)0/5 (0%)0/5 (0%)4/5 (80%)
Placebo (Randomized Withdrawal Period)0/20 (0%)0/20 (0%)11/20 (55%)
Setmelanotide 1.5 mg (Open-Label Extension)0/22 (0%)0/22 (0%)17/22 (77.3%)
Setmelanotide 2.5 mg (Open-Label Extension)0/16 (0%)0/16 (0%)12/16 (75%)
Placebo (Open-Label Extension)0/1 (0%)0/1 (0%)0/1 (0%)
Most frequent other events
Showing 10 of 63
Most frequent other events
EventSetmelanotide 0.5 mg (Double-blind Randomized Treatment)Setmelanotide 1.5 mg (Double-blind Randomized Treatment)Setmelanotide 2.5 mg (Double-blind Randomized Treatment)Placebo (Double-blind Randomized Treatment)Setmelanotide 0.5 mg (Randomized Withdrawal Period)Setmelanotide 1.5 mg (Randomized Withdrawal Period)Setmelanotide 2.5 mg (Randomized Withdrawal Period)Placebo (Randomized Withdrawal Period)Setmelanotide 1.5 mg (Open-Label Extension)Setmelanotide 2.5 mg (Open-Label Extension)Placebo (Open-Label Extension)
Injection site erythemaGeneral disorders3/45/134/86/152/34/104/54/208/226/160/1
Injection site bruisingGeneral disorders3/41/131/83/151/30/100/51/205/220/160/1
Injection site indurationGeneral disorders2/44/132/83/152/32/100/54/206/226/160/1
HeadacheNervous system disorders2/41/130/80/150/30/100/51/202/221/160/1
Injection site oedemaGeneral disorders0/42/131/82/151/32/100/50/206/222/160/1
Injection site pruritusGeneral disorders1/43/130/81/151/31/100/50/202/221/160/1
Injection site swellingGeneral disorders1/40/130/80/150/30/100/50/200/220/160/1
Skin discolourationSkin and subcutaneous tissue disorders1/42/130/80/150/30/100/50/200/220/160/1
Injection site painGeneral disorders0/41/131/81/150/30/100/50/202/220/160/1
Injection site discolourationGeneral disorders0/41/130/80/150/30/100/50/200/222/160/1

Baseline characteristics

Safety Set included all randomized participants who received at least 1 dose of study medication, and had at least one post-dose safety assessment (within Period 2). Participants were classified into groups based on actual treatment received.

Age, Continuous
Age, Continuous(years)Setmelanotide 0.5 mgSetmelanotide 1.5 mgSetmelanotide 2.5 mgPlaceboTotal
Mean21.3 ± 4.1924.1 ± 5.4225.0 ± 9.6230.5 ± 11.9726.4 ± 9.47
Sex: Female, Male
Sex: Female, Male(Participants)Setmelanotide 0.5 mgSetmelanotide 1.5 mgSetmelanotide 2.5 mgPlaceboTotal
Female266721
Male272819
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Setmelanotide 0.5 mgSetmelanotide 1.5 mgSetmelanotide 2.5 mgPlaceboTotal
Hispanic or Latino20114
Not Hispanic or Latino21371436
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Setmelanotide 0.5 mgSetmelanotide 1.5 mgSetmelanotide 2.5 mgPlaceboTotal
American Indian or Alaska Native00000
Asian03003
Native Hawaiian or Other Pacific Islander00000
Black or African American01001
White4981536
More than one race00000
Unknown or Not Reported00000
08

Study locations

5 sites
  • University of California Irvine
    Irvine, California 92617, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Kansas University Medical Center
    Kansas City, Kansas 66160, United States
  • Winthrop University Hospital
    Mineola, New York 11501, United States
  • Vanderbilt University
    Nashville, Tennessee 37203, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Oct 2016, 19 months.

Results were first posted in Jul 2023, 6 years 9 months after primary completion. A results delay was requested in Jan 2018.

Of 11 phase 2 interventional studies under Prader-Willi Syndrome, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 27. This study's 19 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2014
First posted
Dec 8, 2014
StartActual
Mar 19, 2015
Primary completionActual
Oct 26, 2016
CompletionActual
Oct 26, 2016
Results delay requested
Jan 29, 2018
Results first posted
Jul 27, 2023
Last update
Jul 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02311673
Responsible party
Sponsor
First posted
Dec 8, 2014
Start date
Mar 19, 2015
Primary completion
Oct 26, 2016
Completion
Oct 26, 2016
Results posted
Jul 27, 2023
Last update
Jul 27, 2023

Study contacts

David Meeker
study director · Rhythm Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Setmelanotide

Start the discussion